BR0313224A - Pharmaceutical composition containing orally administered sexual dysfunction therapy compound which provides rapid onset of its pharmacological effects - Google Patents

Pharmaceutical composition containing orally administered sexual dysfunction therapy compound which provides rapid onset of its pharmacological effects

Info

Publication number
BR0313224A
BR0313224A BR0313224-2A BR0313224A BR0313224A BR 0313224 A BR0313224 A BR 0313224A BR 0313224 A BR0313224 A BR 0313224A BR 0313224 A BR0313224 A BR 0313224A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition containing
pharmacological effects
sexual dysfunction
orally administered
Prior art date
Application number
BR0313224-2A
Other languages
Portuguese (pt)
Inventor
Nils-Olof Lindberg
Khatarina Lindell
Kristina Thyresson
Alice C Martino
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0313224A publication Critical patent/BR0313224A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA CONTENDO COMPOSTO PARA TERAPIA DA DISFUNçãO SEXUAL PARA SER ADMINISTRADA DE MODO ORAL QUE PROPORCIONA RáPIDO INìCIO DE SEUS EFEITOS FARMACOLóGICOS". Composição farmacêutica contendo composto para terapia da disfunção sexual para ser administrada de modo oral que proporciona rápido início de seus efeitos farmacológicos que compreende pó de cacau, processo para a fabricação da composição e uso da composição na terapia da disfunção sexual."PHARMACEUTICAL COMPOSITION CONTAINING COMPOSITE FOR SEXUAL DYfunction Therapy To Be Administered ORALLY PROVIDING FAST START OF PHARMACOLOGICAL EFFECTS". Pharmaceutical composition containing orally administered sexual dysfunction therapy compound which provides rapid onset of its pharmacological effects comprising cocoa powder, process for the manufacture of the composition and use of the composition in the therapy of sexual dysfunction.

BR0313224-2A 2002-08-05 2003-06-18 Pharmaceutical composition containing orally administered sexual dysfunction therapy compound which provides rapid onset of its pharmacological effects BR0313224A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202365A SE0202365D0 (en) 2002-08-05 2002-08-05 New formulation and use thereof
PCT/SE2003/001022 WO2004012702A1 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof

Publications (1)

Publication Number Publication Date
BR0313224A true BR0313224A (en) 2005-07-05

Family

ID=20288677

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313224-2A BR0313224A (en) 2002-08-05 2003-06-18 Pharmaceutical composition containing orally administered sexual dysfunction therapy compound which provides rapid onset of its pharmacological effects

Country Status (15)

Country Link
EP (1) EP1539096A1 (en)
JP (1) JP2005539008A (en)
CN (1) CN1674866B (en)
AR (1) AR040797A1 (en)
AU (1) AU2003239038B2 (en)
BR (1) BR0313224A (en)
CA (1) CA2495527C (en)
IL (1) IL166031A0 (en)
MX (1) MXPA05000978A (en)
NZ (1) NZ537520A (en)
RU (1) RU2312665C2 (en)
SE (1) SE0202365D0 (en)
TW (1) TW200418470A (en)
WO (1) WO2004012702A1 (en)
ZA (1) ZA200500051B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (en) 2002-07-16 2004-01-29 Bayer Ag Medicinal products containing vardenafil hydrochloride trihydrate
DE102005009240A1 (en) 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with improved pharmacokinetic properties
DE102005009241A1 (en) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with controlled bioavailability
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
DE102010024866A1 (en) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulation for taste masking
EP3299010B1 (en) 2016-09-21 2022-11-09 LTS Lohmann Therapie-Systeme AG Oral dosage form
CA3092458C (en) 2018-03-01 2024-01-30 Lts Lohmann Therapie-Systeme Ag Oral dosage form containing theobromine-free cocoa

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
FR2717387B1 (en) * 1994-03-17 1996-10-18 Hi Pharmtech Process for the production of chewable tablets based on troxerutin, calcium carbonate, calcium phosphate, arginine aspartate, amoxicillin arginine glutamate.
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
ES2105970B1 (en) * 1995-08-02 1998-07-01 S A L V A T Lab Sa ORAL PHARMACEUTICAL COMPOSITION OF CIPROFLOXACINO, NON-AQUEOUS, STABLE AND WITH IMPROVED ORGANOLEPTIC CHARACTERISTICS.
CA2178021C (en) * 1996-04-19 1999-09-28 Theodore H. Stanley Tobacco substitute
WO1998030209A1 (en) * 1997-01-06 1998-07-16 Pfizer Pharmaceuticals Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (en) * 1998-05-15 2000-10-14 Pfizer PHARMACEUTICAL FORMULATIONS.
JP2000095710A (en) * 1998-09-21 2000-04-04 Taisho Pharmaceut Co Ltd Oral solid preparation mixed with cacao powder
JP2000119198A (en) * 1998-10-16 2000-04-25 Eisai Co Ltd Phosphodiesterase inhibitor-containing peroral preparation hiding bitterness or the like
US6060094A (en) * 1998-10-30 2000-05-09 Nestec S.A. Method of reducing fat in fat-based coating for confectionery products
SE9803986D0 (en) 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
SI20109A (en) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CA2378257A1 (en) 1999-08-10 2001-02-15 William E. Sponsel Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP2001114668A (en) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd Chocolate preparation
WO2001049292A1 (en) 1999-12-30 2001-07-12 Tap Holdings, Inc. Oral mucosal dosage forms of apomorphine
AU2001273545A1 (en) 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
JP2002193839A (en) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd Cocoa pharmaceutical preparation
AR032556A1 (en) * 2001-02-08 2003-11-12 Pharmacia Corp IMMEDIATE ACTION DRUG FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa

Also Published As

Publication number Publication date
CA2495527C (en) 2008-12-30
NZ537520A (en) 2006-11-30
AU2003239038A1 (en) 2004-02-23
AR040797A1 (en) 2005-04-20
WO2004012702A1 (en) 2004-02-12
TW200418470A (en) 2004-10-01
RU2005102835A (en) 2005-08-10
MXPA05000978A (en) 2005-12-12
AU2003239038B2 (en) 2008-01-03
CN1674866A (en) 2005-09-28
EP1539096A1 (en) 2005-06-15
CN1674866B (en) 2012-09-26
IL166031A0 (en) 2006-01-15
JP2005539008A (en) 2005-12-22
RU2312665C2 (en) 2007-12-20
ZA200500051B (en) 2006-12-27
SE0202365D0 (en) 2002-08-05
CA2495527A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
BR9808888A (en) Dosage forms and method of improving male erectile dysfunction
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
AR041725A1 (en) PREVENTION, TREATMENT OF SINUCLEINOPATIC DISEASE AND PHARMACOLOGICAL COMPOSITION
MY120279A (en) Use of a celecoxib composition for fast pain relief
PL401469A1 (en) Azabicyclic derivative, method of its production, its use in medicine and derivative composition
GEP20063799B (en) Tropane derivatives useful in therapy
AR015820A1 (en) SPECIFICATIONS OF BUDESONIDE, PHARMACEUTICAL COMPOSITION, USE OF SUCH PARTICLES FOR THE MANUFACTURE OF MEDICINES, METHOD FOR THE TREATMENT OF RESPIRATORY UNTRASTORN AND PROCESS FOR THE PREPARATION OF PARTICLES
MY119403A (en) Novel compounds with analgesic effect.
PE20001032A1 (en) COMPOSITIONS AND METHODS TO TREAT PULMONARY DISEASES
AR033548A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A LIPASA INHIBITOR, A PROCEDURE FOR THEIR PREPARATION, TRANSPORTABLE EQUIPMENT IN A KIT MODE, THE USE OF SUCH COMPOSITION IN THE MANUFACTURE OF MEDICINES, A LIPASE INHIBITOR AND A BICYCLE SEQUOSTRANT
SG152257A1 (en) Topical preparation containing ambroxol
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BR0214289A (en) Beverage composition comprising a defined boron compound, method of preparing it, kit comprising it and use thereof in the manufacture of a medicament
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
BR0109672A (en) Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal
AR006401A1 (en) PIRROLOPYROLONE COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND IN THERAPY, PROCESSES FOR ITS PREPARATION AND INTERMEDIARY COMPOUNDS FOR SUCH PROCESSES.
GB0406384D0 (en) Composition for reducing appetite in mammals comprising proxyanidin
AR012417A1 (en) PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION AND PROCEDURE FOR ITS PRODUCTION.
TR199802769T2 (en) Topical composition containing a combination of terpenoid compounds and antihistamine compounds.
ES2191987T3 (en) DOSAGE FORMS OF RIBAVIRINA SOLIDAS, ADMINISTRABLE ORALALLY, AND MANUFACTURING PROCEDURE.
HUP0000137A2 (en) Controller-release pharmaceutical composition containing anangetics
BR0313224A (en) Pharmaceutical composition containing orally administered sexual dysfunction therapy compound which provides rapid onset of its pharmacological effects
HUP9700806A2 (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine and process for the preparation thereof
BR0107899A (en) Process for producing an active ingredient preparation comprising ibuprofen, preparation of active ingredient, use thereof, pharmaceutical preparation, use thereof, process for producing solid dosage forms, and, solid dosage form
WO2000008007A3 (en) Cyclopentabenzofuran derivatives and their use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM OS ARTIGOS 8O, 11 E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.